![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
A well-known, four-year study found popular arthritis drug Celebrex no more dangerous for the heart than older drugs in its same classification – commonly called NSAIDs.
Early-stage osteoarthritis drug wins prestigious innovation award
UK-based biotech company rewarded for unique approach to drug development by UK Government’s innovation bodyAKL Research and Development (AKLRD) today announces its investigational medicine for osteoarthritis (OA) has...
App helpt jongeren hun medicijnen juist in te nemen
Een app waarmee chronisch zieke jongeren kunnen chatten met hun apotheker helpt hen om hun medicijnen op tijd en op de juiste manier in te nemen. Onderzoeker Richelle Kosse van de Universiteit Utrecht promoveert vandaag...
Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market
Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat opioid use disorder, following a US court’s decision to open the market...
FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths
Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, its investigational CD123 x CD3 bispecific antibody, in patients with relapsed or refractory acute myeloid...
Bacteria living on insects could provide new antibiotics
Insects harbor bacteria that protect them from infection. Tapping this source could yield new antibiotics to combat the growing threat of drug resistance.
Prix Galien Pharmaceutical Award 2019
In Nederland wordt sinds 1992 elk jaar de Galenus Geneesmiddelenprijs uitgereikt. Vanaf 2018, bij het 25-jarig bestaan van de Galenusprijzen, is de naam, naar internationaal voorbeeld, definitief omgedoopt in Prix...
Upadacitinib Gets FDA’s Priority Review for Treatment of Moderate to Severe RA
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for upadacitinib (AbbVie), an investigational oral JAK1-selective inhibitor, for the treatment of moderate to severe...
Dit zijn de genomineerden voor de Dutch Marketing Awards tot nu toe
Van vier van de zeven categorieën is de shortlist gepubliceerd.
Merck’s Keytruda fails late-stage study in liver cancer patients
Merck & Co Inc said on Tuesday its cancer drug Keytruda failed the main goals of a late-stage trial and did not extend life of patients with a type of liver cancer.
Dapagliflozine nuttig voor deel patiënten diabetes type 1
De Committee for Medicinal Products for Human Use (CHMP) beveelt de inzet van de SGLT-2-remmer dapagliflozine aan als eerste orale additionele therapie – naast insuline – voor bepaalde patiënten met diabetes mellitus...
Onderzoek UMC Utrecht maakt gepersonaliseerde medicijnen mogelijk
Utrechtse onderzoekers hebben aangetoond dat een buiten het lichaam uit stamcellen gekweekt mini-orgaantje gebruikt kan worden om de effectiviteit van medicijnen te voorspellen. Dat blijkt uit hun nieuwe studie naar...
Intercept’s NASH liver fibrosis drug shows promise at Phase 3
Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH), sending the company’s shares up by...
Pfizer and Eli Lilly's chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial
US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 trial of patients with moderate to severe chronic low back pain (CLBP). Treatment with 10mg of tanezumab...
Keytruda falls short at Phase 3 in advanced liver cancer
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive care, failed to meet its primary endpoints of overall survival or...
Persbericht IVM: Janine Budding benoemd tot Adviseur Marketingcommunicatie Instituut Verantwoord Medicijngebruik (IVM)
Instituut Verantwoord Medicijngebruik (IVM), hét instituut voor goed, veilig en doelmatig medicijngebruik, heeft Janine Budding (50) aangesteld als Adviseur Marketingcommunicatie. In haar nieuwe functie is Janine...
PRESS RELEASE: Reboocon Bionics wins start-up pitch contest and receives the AXON Innovation for Health Award 2019
Hilversum, 15 February 2019 Reboocon has won the AXON Innovation for Health Award 2019 for the best start-up pitch at the sixth edition of Innovation for Health and the third edition of Global Investor Forum...
FDA warns doctor for illegally marketing unapproved implantable device
Today, the U.S. Food and Drug Administration issued a warning letter to Mark Berman, M.D., of Beverly Hills, California, for illegally marketing an unapproved implantable device, the Pocket Protector, that Dr. Berman...
